Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 3NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Neoplasms 3Thyroid Cancer, Papillary 1Neoplasm Metastasis 1Hypothyroidism 1Adenocarcinoma, Follicular 1

Interventions

Magnetic Resonance Spectroscopy 6Iodine-131 3Fluorodeoxyglucose F18 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3Trastuzumab 2Radiotherapy 2trametinib 1tipifarnib 1tanespimycin 1sargramostim 1romidepsin 1omipalisib 1gallium Ga 68 dotatate 1cediranib 1cabozantinib 1aldesleukin 1aflibercept 1Vorinostat 1Triiodothyronine 1Thyrotropin Alfa 1Tamoxifen 1Sunitinib 1Specimen Handling 1Sorafenib 1Rosiglitazone 1Ritonavir 1Pharmacogenomic Testing 1Nivolumab 1Lenalidomide 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Adenocarcinoma, Follicular × Thyrotropin Alfa × Clear all
NCT00085293 2018-11-29

Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131

National Cancer Institute (NCI)

Phase 2 Completed
12 enrolled 4 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡